Immatics N.V. IMTX
Immatics N.V. (Nasdaq: IMTX) is an oncology drug developer. Its lead program, anzu-cel (anzutresgene autoleucel, IMA203), is in Phase 3 for second-or-later-line advanced cutaneous melanoma (PRAME-positive); also metastatic uveal melanoma (Phase 2).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| anzu-cel (IMA203) - SUPRAME | 2L advanced cutaneous melanoma | cell therapy | Phase 3 |
| anzu-cel (IMA203) - uveal melanoma | metastatic uveal melanoma | cell therapy | Phase 2 |
| IMA203CD8 (GEN2) | 2L metastatic solid cancers beyond melanoma (gynecologic and others) | cell therapy | Phase 1 |
| IMA402 | PRAME-positive solid tumors incl. 2L melanoma, gynecologic cancers | protein/peptide | Phase 1 |
| anzu-cel + mRNA-4203 (Moderna PRAME cell therapy enhancer) | PRAME-positive solid tumors | cell therapy | Phase 1 |
| IMA402 + IMA401 (MAGEA4/8 bispecific) | squamous NSCLC and potentially others | protein/peptide | Pre-clinical |
Recent results and decisions
- Aug 18, 2026n/a SUPRAME protocol amendment per FDA feedback: single streamlined final PFS analysis (90% power) replaces interim and final; ~90 more patients (total ~450) to power OS, because PFS events are accruing more slowly than modeled.
As a result, Immatics intends to replace the previously planned interim and final PFS analyses with a single streamlined final analysis, now based on a lower prespecified number of PFS events while maintaining a robust power of 90% for the primary endpoint.
Filing - Aug 18, 2026positive Updated Phase 1b (ASCO 2026): 56% confirmed ORR, mDOR 14.6 months, mPFS 6.1 months, mOS 16.2 months, 24-month OS rate 46%.
Updated Phase 1b clinical data presented at the 2026 ASCO Annual Meeting showed durable anti-tumor activity at longer follow-up in metastatic melanoma, including 56% confirmed ORR, 14.6 months mDOR, 6.1 months mPFS and 16.2 months mOS.
Filing - Aug 18, 2026positive Updated Phase 1 (ASCO 2026) in gynecologic cancers: 63% ORR, 50% confirmed ORR, four complete responses.
Updated Phase 1 data in hard-to-treat gynecologic cancers presented at the 2026 ASCO Annual Meeting demonstrated anti-tumor activity at clinically relevant doses, including 63% ORR and 50% confirmed ORR, four complete responses and the longest ongoing response at 12 months.
Filing
3 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 oncology companies
- Merck & Co., Inc. MRK
- Astrazeneca PLC AZN
- Bristol Myers Squibb Co BMY
- BeOne Medicines Ltd. ONC
- Revolution Medicines, Inc. RVMD
- Genmab A/S GMAB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.